

July 14, 2025

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Scrip Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Intimation of Board Meeting under Regulation 29 & 50 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

---

Pursuant to Regulation 29 & 50 of the Listing Regulations, we wish to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Thursday, July 31, 2025, inter-alia to consider:

- i. and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30, 2025; and
- ii. declaration of interim dividend, if any, for the financial year 2025-26.

Further, in continuation of our earlier letter dated June 26, 2025 under subject ‘Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till August 2, 2025.

The above notice is also being uploaded on the website of the Company at [www.mankindpharma.com](http://www.mankindpharma.com).

You are requested to take note of the same.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Hitesh Kumar Jain**  
**Company Secretary and Compliance Officer**